Answers are grounded in this paper and cite their sources.
Machine learning framework identifies clonal expansion in T-cells across cancers, suggesting wide applicability without TCR data.
Advances in single-cell sequencing have enabled detailed characterization of T-cell clonal dynamics in cancer. However, analyses aiming to link transcriptional landscape to T-cell clonality remain limited by confounding factors unequally controlled in different studies. To address this challenge, we developed scXpand, the first machine learning framework for pan-cancer detection of T-cell clonal expansion directly from single-cell RNA sequencing (scRNA-seq), without paired T-cell receptor (TCR) sequencing. Trained and tested using our in-house-constructed human pan-cancer database of paired scRNA/TCR-seq profiles from 2.6 million T cells, scXpand demonstrates robust and accurate detection of clonal expansion across tissues and T-cell subtypes. Applied to datasets lacking TCR sequencing, scXpand predictions correspond with known characteristics of the tumor microenvironment. Overall, scXpand is the first framework to detect T-cell clonal expansion across cancers directly from scRNA-seq, enabling broad use on datasets lacking scTCR-seq, while supporting scalable, memory-efficient processing, including pre-trained models with user-friendly documentation for flexible applications.
No takes yet. Share an insight, caveat, or question.
Shorer et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: